IL-6 or IL-6 receptor blockers are already used successfully in the treatment of RA, and are proof of concept that damping down IL-6, a product of the NF-κB pro-inflammatory cascade, can improve clinical symptoms. Here, IL6 is linked to rheumatoid arthritis.